Title: Selective inhibition of soluble TNF using XPro1595 relieves pain and attenuates cerulein-
induced pathology in mice
Version: 3 Date: 09 Mar 2021
Reviewer:  Mustafa Kaplan
Reviewer's report:
Dear Editor,
I would like to express that I find the subject and method of study very good.
However, it is very important to make some corrections in terms of method regarding the writing.
If these issues are summarized;
1. It is seen that the abstract part of the article is rather irregular and insufficient. It should be
shortened and edited in accordance with the writing principles. The method part is not mentioned
at all in the abstract part. Also, in the abstract part, the background part should not be that long. In
addition, the abstract should include the outline of the article and should not contain unnecessary
information.
2. The introduction of the article is quite long and needs to be shortened.
3. The approval obtained from the ethics committee for experimental animals should be given
in detail.
4. In the methodology part of the article, detailed information about the methodology should be
given, such as how many groups the experimental animals are divided into.
5. Is there validity of the pancreatitis scoring used in the article? Detailed information should
be given about where it was taken from.
6. In the results part of the article, rather than giving the discussion obtained from the rats, the
efficacy of the relevant substance used was mentioned.
7. Detailed descriptions of how useful Xpro1595 is. Most of the information given in the result
should perhaps be given in the discussion section.
8. When the result part is this long, of course the discussion part was also just as short. However,
the discussion section should be longer.
9. As a study of experimental animals, although the subject is quite interesting, beautiful and
well written, its methodology is unfortunately poorly written.
10. As a result, if the desired corrections are made, the article must be accepted for publication.
Sincerly.
Title: Selective inhibition of soluble TNF using XPro1595 relieves pain and attenuates cerulein-
induced pathology in mice
Version: 3 Date: 09 Mar 2021
Reviewer:  Mustafa Kaplan
Reviewer's report:
Dear Editor,
I would like to express that I find the subject and method of study very good.
However, it is very important to make some corrections in terms of method regarding the writing.
If these issues are summarized;
1. It is seen that the abstract part of the article is rather irregular and insufficient. It should be
shortened and edited in accordance with the writing principles. The method part is not mentioned
at all in the abstract part. Also, in the abstract part, the background part should not be that long. In
addition, the abstract should include the outline of the article and should not contain unnecessary
information.
2. The introduction of the article is quite long and needs to be shortened.
3. The approval obtained from the ethics committee for experimental animals should be given
in detail.
4. In the methodology part of the article, detailed information about the methodology should be
given, such as how many groups the experimental animals are divided into.
5. Is there validity of the pancreatitis scoring used in the article? Detailed information should
be given about where it was taken from.
6. In the results part of the article, rather than giving the discussion obtained from the rats, the
efficacy of the relevant substance used was mentioned.
7. Detailed descriptions of how useful Xpro1595 is. Most of the information given in the result
should perhaps be given in the discussion section.
8. When the result part is this long, of course the discussion part was also just as short. However,
the discussion section should be longer.
9. As a study of experimental animals, although the subject is quite interesting, beautiful and
well written, its methodology is unfortunately poorly written.
10. As a result, if the desired corrections are made, the article must be accepted for publication.
Sincerly.
Please review this paper.
user
Title: Selective inhibition of soluble TNF using XPro1595 relieves pain and attenuates cerulein-
induced pathology in mice
Version: 3 Date: 09 Mar 2021
Reviewer:  Mustafa Kaplan
Reviewer's report:
Dear Editor,
I would like to express that I find the subject and method of study very good.
However, it is very important to make some corrections in terms of method regarding the writing.
If these issues are summarized;
1. It is seen that the abstract part of the article is rather irregular and insufficient. It should be
shortened and edited in accordance with the writing principles. The method part is not mentioned
at all in the abstract part. Also, in the abstract part, the background part should not be that long. In
addition, the abstract should include the outline of the article and should not contain unnecessary
information.
2. The introduction of the article is quite long and needs to be shortened.
3. The approval obtained from the ethics committee for experimental animals should be given
in detail.
4. In the methodology part of the article, detailed information about the methodology should be
given, such as how many groups the experimental animals are divided into.
5. Is there validity of the pancreatitis scoring used in the article? Detailed information should
be given about where it was taken from.
6. In the results part of the article, rather than giving the discussion obtained from the rats, the
efficacy of the relevant substance used was mentioned.
7. Detailed descriptions of how useful Xpro1595 is. Most of the information given in the result
should perhaps be given in the discussion section.
8. When the result part is this long, of course the discussion part was also just as short. However,
the discussion section should be longer.
9. As a study of experimental animals, although the subject is quite interesting, beautiful and
well written, its methodology is unfortunately poorly written.
10. As a result, if the desired corrections are made, the article must be accepted for publication.
Sincerly.
assistant